Tissue Repair Gel in Venous Leg Ulcers (US)
TR Therapeutics · NCT06707090
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 3
- Target enrollment
- 312
- US sites recruiting
- 24
- Study start
- January 28, 2025
- Record last updated
- February 12, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.
Being studied: TR987 0.1% gel + Standard of Care; Standard of care
Conditions: Venous Leg Ulcer; Venous Ulcer; Venous Stasis Ulcer; Venous Stasis; Wound Heal; Wounds; Venous Insufficiency of Leg; Non-healing Wound
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Adults 18 years and older
- Venous insufficiency has been clinically diagnosed clinically and medically confirmed.
- Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control.
- The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization.
- Target ulcer age must be ≥ 4 weeks at Screening.
- Participants must have adequate arterial flow as confirmed by ABI/TBI, TB, SPP, TCPo2, or Duplex Doppler.
- Body mass index (BMI) ≤ 50 kg/m2.
- HbA1C ≤12%.
Exclusion Criteria
- Target ulcer has been treated with prohibited medications or therapies.
- History of radiation at the target ulcer site.
- Target ulcer decreases in area by 30% or more during screening period.
- History of osteomyelitis at the target ulcer within 6 months of screening.
- Participants considered nutritionally deficient.
Recruiting US locations
Clincial Research Site 43C
Castro Valley, CA 94546
Site contact: info@trtherapeutics.com
Clincial Research Site 14
Fresno, CA 93710
Site contact: info@trtherapeutics.com
Clincial Research Site 11
Los Angeles, CA 90063
Site contact: info@trtherapeutics.com
Clincial Research Site 43A
San Francisco, CA 94115
Site contact: info@trtherapeutics.com
Clincial Research Site 43B
San Francisco, CA 94117
Site contact: info@trtherapeutics.com
Clincial Research Site 54
Vista, CA 92081
Site contact: info@trtherapeutics.com
Clincial Research Site 40
Jacksonville, FL 32209
Site contact: info@trtherapeutics.com
Clincial Research Site 19
Miami, FL 33150
Site contact: info@trtherapeutics.com
Clincial Research Site 26
Miami, FL 33156
Site contact: info@trtherapeutics.com
Clincial Research Site 13
Pembrook Pines, FL 33026
Site contact: info@trtherapeutics.com
Clincial Research Site 34
Chicago, IL 60649
Site contact: info@trtherapeutics.com
Clincial Research Site 10
O'Fallon, IL 62269
Site contact: info@trtherapeutics.com
Clincial Research Site 49
Springfield, IL 62704
Site contact: info@trtherapeutics.com
Clincial Research Site 04
Bossier City, LA 71111
Site contact: info@trtherapeutics.com
Clincial Research Site 01
Lafayette, LA 70507
Site contact: info@trtherapeutics.com
Clincial Research Site 07
D'Iberville, MS 39540
Site contact: info@trtherapeutics.com
Clincial Research Site 02
McComb, MS 39648
Site contact: info@trtherapeutics.com
Clincial Research Site 30
New York, NY 10019
Site contact: info@trtherapeutics.com
Clincial Research Site 37
Syosset, NY 11791
Site contact: info@trtherapeutics.com
Clincial Research Site 28
Tulsa, OK 74137
Site contact: info@trtherapeutics.com
Clincial Research Site 36
Philadelphia, PA 19107
Site contact: info@trtherapeutics.com
Clincial Research Site 24
Fort Worth, TX 76104
Site contact: info@trtherapeutics.com
Clincial Research Site 32
Houston, TX 27707
Site contact: info@trtherapeutics.com
Clincial Research Site 18
Suffolk, VA 23434
Site contact: info@trtherapeutics.com
Study contacts (from the official record)
- Anhthu Nguyen Vice President, Global Clinical Operations · (+61) 280 034 554 · anhthu.nguyen@trtherapeutics.com